Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

[Lower incidence of severe damage to target organs in mexican patients with systemic sclerosis and diffuse skin affection].

Rojas-Serrano J, Codina-Velásquez H, Medrano-Ramírez G, Abraham Simón J, Vera-Lastra O, Vázquez-Mellado J.

Reumatol Clin. 2008 Jan;4(1):3-7. doi: 10.1016/S1699-258X(08)71788-1. Epub 2008 Oct 28. Spanish.

2.

Severe organ involvement in systemic sclerosis with diffuse scleroderma.

Steen VD, Medsger TA Jr.

Arthritis Rheum. 2000 Nov;43(11):2437-44.

3.

Factors predicting development of renal involvement in progressive systemic sclerosis.

Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP.

Am J Med. 1984 May;76(5):779-86.

PMID:
6372452
4.

Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity.

Caramaschi P, Canestrini S, Martinelli N, Volpe A, Pieropan S, Ferrari M, Bambara LM, Carletto A, Biasi D.

Rheumatology (Oxford). 2007 Oct;46(10):1566-9. Epub 2007 Aug 10.

PMID:
17693443
5.

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, Mayes M, White B, Wigley F, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.

Arthritis Rheum. 2002 Nov;46(11):2983-9.

6.

A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.

Derk CT, Huaman G, Jimenez SA.

Br J Dermatol. 2008 May;158(5):1063-8. doi: 10.1111/j.1365-2133.2008.08452.x. Epub 2008 Feb 16.

PMID:
18284395
7.

Clinical manifestations of systemic sclerosis.

Steen VD.

Semin Cutan Med Surg. 1998 Mar;17(1):48-54. Review.

PMID:
9512107
8.

Determinants of morbidity and mortality of systemic sclerosis in Canada.

Al-Dhaher FF, Pope JE, Ouimet JM.

Semin Arthritis Rheum. 2010 Feb;39(4):269-77. doi: 10.1016/j.semarthrit.2008.06.002. Epub 2008 Aug 15.

PMID:
18706680
9.

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP.

Arthritis Rheum. 2007 Jul;56(7):2422-31.

10.

Clinical approach to scleroderma.

White B.

Semin Cutan Med Surg. 1998 Sep;17(3):213-8.

PMID:
9759679
11.

Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.

Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J; Canadian Scleroderma Research Group.

Arthritis Care Res (Hoboken). 2011 Jan;63(1):142-9. doi: 10.1002/acr.20336.

12.
13.

Localized scleroderma in childhood is not just a skin disease.

Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, Espada G, Corona F, Mukamel M, Vesely R, Musiej-Nowakowska E, Chaitow J, Ros J, Apaz MT, Gerloni V, Mazur-Zielinska H, Nielsen S, Ullman S, Horneff G, Wouters C, Martini G, Cimaz R, Laxer R, Athreya BH; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES).

Arthritis Rheum. 2005 Sep;52(9):2873-81.

14.

[Progressive systemic scleroderma--prognosis determining involvement of internal organ systems].

Mittag M, Haustein UF.

Hautarzt. 1998 Jul;49(7):545-51. Review. German.

PMID:
9715381
15.

Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis.

Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R.

J Med Assoc Thai. 2002 Nov;85(11):1204-9.

PMID:
12546318
16.

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, Espigado I, Hertenstein B, Hiepe F, Kashyap A, Kötter I, Marmont A, Martinez A, Pascual MJ, Gratwohl A, Prentice HG, Black C, Tyndall A.

Ann Rheum Dis. 2001 Jun;60(6):577-84.

17.

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.

Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally E, Varga J, Weiner SR, Andrews B, Abeles M, Furst DE.

Arthritis Rheum. 2000 Nov;43(11):2445-54.

18.

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.

Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, Medsger TA Jr.

Arthritis Rheum. 2007 Aug;56(8):2740-6.

19.

[Antiendothelial antibodies in systemic scleroderma and Raynaud's disease].

Salozhin KV, Shcherbakov AB, Nasonov EL, Kolesova NV, Romanov IuA, Guseva NG.

Ter Arkh. 1995;67(5):54-7. Russian.

PMID:
7638782
20.

Extracorporeal photochemotherapy in systemic sclerosis and severe morphea.

Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E.

Dermatology. 1995;191(1):25-31.

PMID:
8589478

Supplemental Content

Support Center